Neuropsychiatric Symptoms Due to Major and Mild Neurocognitive Disorders

  • Ana Hategan
  • James A. Bourgeois
  • Tracy Cheng
  • Julie Young


The management of mild and major neurocognitive disorders often involves the assessment and management of neuropsychiatric symptoms, also known as behavior and psychological symptoms of dementia (BPSD), as these symptoms commonly occur during the course of the neurocognitive disorders. Because neuropsychiatric symptoms often impact on the ability of a caregiver to manage at home, it is very important that they are assessed and treated promptly. The following section provides a review of the evaluation, assessment, impact, and management of common neuropsychiatric symptoms seen in various neurocognitive disorders.


Neuropsychiatric symptoms Responsive behaviors Neurocognitive disorders BPSD Agitation Aggression Mild and major neurocognitive disorders 


  1. 1.
    Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA. 2002;288(12):1475–83.CrossRefPubMedGoogle Scholar
  2. 2.
    David ND, Lin F, Porsteinsson AP. Trajectories of neuropsychiatric symptoms and cognitive decline in mild cognitive impairment. Am J Geriatr Psychiatry. 2016;24(1):70–80.CrossRefPubMedGoogle Scholar
  3. 3.
    Zhao QF, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264–71.CrossRefPubMedGoogle Scholar
  4. 4.
    Charemboon T, Phanasathit M. Prevalence of neuropsychiatric symptoms in Alzheimer’s disease: a cross-sectional descriptive study in Thailand. J Med Assoc Thai. 2014;97(5):560–5.Google Scholar
  5. 5.
    Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–14.CrossRefPubMedGoogle Scholar
  6. 6.
    Cohen-Mansfield J. Instruction manual for the Cohen-Mansfield Agitation Inventory (CMAI) [internet]. 1991. Accessed 14 Oct 2017.
  7. 7.
    Reisberg B, Monteiro I, Torossian C, Auer S, Shulman MB, Ghimire S, et al. The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical review. Dement Geriatr Cogn Disord. 2014;38(1–2):89–146.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry. 1987;48(Suppl):9–15.PubMedGoogle Scholar
  9. 9.
    Gauthier S, Cummings JL, Ballard C, Brodaty H, Grossberg G, Robert P, et al. Management of behavioral problems in Alzheimer’s disease. Int Psychogeriatr. 2010;22(3):346–72.CrossRefPubMedGoogle Scholar
  10. 10.
    Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3):243–54.CrossRefPubMedGoogle Scholar
  11. 11.
    Berman K, Brodaty H, Withall A, Seeher K. Pharmacologic treatment of apathy in dementia. Am J Geriatr Psychiatry. 2012;20(2):104–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Hermann N, Rothenburg LS, Black SE, Ryan M, Liu BA, Busto UE, et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol. 2008;28(3):296–301.CrossRefGoogle Scholar
  13. 13.
    Frakey LL, Salloway S, Buelow M, Malloy P. A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer’s disease. J Clin Psychiatry. 2012;73(6):796–801.CrossRefPubMedGoogle Scholar
  14. 14.
    Sadak TI, Katon J, Beck C, Cochrane BB, Borson S. Key neuropsychiatric symptoms in common dementias: prevalence and implications for caregivers, clinicians, and health systems. Res Gerontol Nurs. 2014;7(1):44–52.CrossRefPubMedGoogle Scholar
  15. 15.
    Kazui H, Yoshiyama K, Kanemoto H, Suzuki Y, Sato S, Hashimoto M, et al. Differences of behavioral and psychological symptoms of dementia in disease severity in four major dementias. PLoS One. 2016;11(8):e0161092.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Gallagher D, Fischer CE, Iaboni A. Neuropsychiatric symptoms in mild cognitive impairment: an update on prevalence, mechanisms and clinical significance. Can J Psychiatry. 2017;62(3):161–9.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Starkstein SE, Mizrahi R, Capizzano AA, Acion L, Brockman S, Power B. Neuroimaging correlates of apathy and depression in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 2009;21(3):259–65.CrossRefPubMedGoogle Scholar
  18. 18.
    Hahn C, Lim HK, Won WY, Ahn KJ, Jumg WS, Lee CUK. Apathy and white matter integrity in Alzheimer’s disease: a whole brain analysis with tract-based spatial statistics. PLoS One. 2013;8(1):e53493. Scholar
  19. 19.
    Theleritis C, Politis A, Siarkos K, Lyketsos CG. A review of neuroimaging findings of apathy in Alzheimer’s disease. Int Psychogeriatr. 2014;26(2):195–207.CrossRefPubMedGoogle Scholar
  20. 20.
    Franceschi M, Anchisi D, Pelati O, Zuffi M, Matarrese M, Moresco RM, et al. Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Ann Neurol. 2005;57(2):216–25.CrossRefPubMedGoogle Scholar
  21. 21.
    Peters F, Perani D, Herholz K, Holthoff V, Beuthien-Baumann B, Sorbi S, et al. Orbitofrontal dysfunction related to both apathy and disinhibition in frontotemporal dementia. Dement Geriatr Cogn Disord. 2006;21:373–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Yury CA, Fisher JE. Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia. Psychother Psychosom. 2007;76(4):21–8.CrossRefGoogle Scholar
  23. 23.
    Herrmann N, Lanctôt KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013;5(Suppl 1):S5.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Seitz DP, Adunuri N, Gill SS, Gruneir A, Hermann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;(2):CD008191.Google Scholar
  25. 25.
    Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease. JAMA. 2003;289(2):210–6. Scholar
  26. 26.
    Pinheiro D. [Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)]. Encephale. 2008;34(4):409–15.Google Scholar
  27. 27.
    Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43.CrossRefPubMedGoogle Scholar
  28. 28.
    Gill SS, Bronskill SE, Normand ST, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775–86.CrossRefPubMedGoogle Scholar
  29. 29.
    Lenze EJ. Treating depression in older adults with dementia. J Am Geriatr Soc. 2011;59(4):754–5.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Madhusoodanan S, Ting MB. Pharmacological management of behavioral symptoms associated with dementia. World J Psychiatry. 2014;4(4):72–9.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Lonergan E., Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2009; 8(3).Google Scholar
  33. 33.
    Olazaran J, Reisberg B, Clare L, Cruz I, Pena-Casanova J, Del Ser T, et al. Nonpharmacological therapies in Alzheimer’s disease: a systematic review of efficacy. Dement Geriatr Cogn Disord. 2010;30:11–78.CrossRefGoogle Scholar
  34. 34.
    de Oliveria AM, Radanovic M, de Mello PCH, Buchain PC, Vizzott ADB, Celestino DL. Nonpharmacological interventions to reduce behavioral and psychological symptoms of dementia: a systematic review. Biomed Res Int. 2015;2015:218980.Google Scholar
  35. 35.
    Kales HC, Gitlin LN, Lyketsos CG, Althouse EP. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–9.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Cheng ST. Dementia caregiver burden: a research update and critical analysis. Curr Psychiatry Rep. 2017;19(9):64.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Wu YH, Swaab DF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer’s disease. Sleep Med. 2007;8:623–36.CrossRefPubMedGoogle Scholar
  39. 39.
    Deschenes CL, McCurry SM. Current treatments for sleep disturbances in individuals with dementia. Curr Psychiatry Rep. 2009;11(1):20–6.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Gehrman PR, Connor DJ, Martin JL, Shochat T, Corey-Bloom J, Anncoli-Isreal S. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am J Geriatr Psychiatry. 2009;17:166–9.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep. 2003;26(7):893–901.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Irwin MR, Cole JC, Nicassio PM. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged and in older adults 55+ years of age. Health Psychol. 2006;25(1):3–14.CrossRefPubMedGoogle Scholar
  43. 43.
    Gitlin LN, Kales HC, Lyketsos CG, Althouse EP. Managing behavioral symptoms in dementia using nonpharmacologic approaches: an overview. JAMA. 2012;308(19):2020–9.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Finkel SI. Behavioral and psychological symptoms of dementia (BPSD): a current focus for clinicians, researchers, caregivers, and governmental agencies. In: Miyoshi K, Shapiro CM, Gaviria M, Morita Y, editors. Contemporary neuropsychiatry. Tokyo: Springer; 2001. p. 200–10.CrossRefGoogle Scholar
  45. 45.
    Volicer L, Hurley AC. Review article: management of behavioral symptoms in progressive degenerative dementias. J Gerontol. 2003;58(9):M837–45.CrossRefGoogle Scholar
  46. 46.
    Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer’s disease: Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46(2):210–5.CrossRefPubMedGoogle Scholar
  47. 47.
    Mortby ME, Burns R, Eramudugolla R, Ismail X, Anstey KJ. Neuropsychiatric symptoms and cognitive impairment: understanding the importance of co-morbid symptoms. J Alzheimers Dis. 2017;59(1):141–53.CrossRefPubMedGoogle Scholar
  48. 48.
    Forrester SN, Gallo JJ, Smith GS, Leoutsakos JM. Patterns of neuropsychiatric symptoms in mild cognitive impairment and risk of dementia. Am J Geriatr Psychiatry. 2016;24:117–25.CrossRefPubMedGoogle Scholar
  49. 49.
    Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12:195–202.CrossRefPubMedGoogle Scholar
  50. 50.
    Bertrand E, Duinkerken E, Landeira-Fernandez J, Dourado MCN, Santos RL, Laks J, et al. Behavioral and psychological symptoms impact clinical competence in Alzheimer’s disease. Front Aging Neurosci. 2017;9:182.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ana Hategan
    • 1
  • James A. Bourgeois
    • 2
    • 3
  • Tracy Cheng
    • 4
  • Julie Young
    • 5
  1. 1.Department of Psychiatry and Behavioural NeurosciencesMcMaster UniversityHamiltonCanada
  2. 2.Department of PsychiatryBaylor Scott and White Health Central Texas DivisionDallasUSA
  3. 3.Department of PsychiatryTexas A&M University Health Science Center, College of MedicineTempleCanada
  4. 4.St. Joseph’s Healthcare Hamilton, McMaster UniversityHamiltonUSA
  5. 5.Mercy San Juan Medical CenterFarmingtonUSA

Personalised recommendations